Anupam Batra1, Scott Ernst1, Kylea Potvin1, Ricardo Fernandes1, Nicholas Power2, James Vanhie3, Eric Winquist1. 1. Division of Medical Oncology, Department of Oncology, Western University and London Health Sciences Centre, London, ON, Canada. 2. Division of Urology, Department of Surgery, Western University and London Health Sciences Centre, London, ON, Canada. 3. London Health Sciences Centre, London, ON, Canada.
Abstract
INTRODUCTION: Intensified chemotherapy improved outcomes for men with poor-prognosis metastatic germ cell cancer (GCC) and unfavorable tumor marker decline after one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy in the GETUG-13 trial. Herein, we report our experience to date using a similar approach. METHODS: Patients were identified from our electronic GCC database. Men with poor-prognosis GCC and unfavorable tumor marker decline were offered intensified chemotherapy consisting of T-BEP (three cycles) plus paclitaxel, ifosfamide, and cisplatin (TIP) (one cycle), along with prophylactic granulocyte-colony stimulating factor (G-CSF) and resection of residual masses. Cisplatin, etoposide, and ifosfamide (PEI) replaced the last cycle of T-BEP for bleomycin pulmonary concerns. Serious toxicities, progression-free survival, and overall survival were evaluated retrospectively. RESULTS: Ten patients with poor-prognosis GCC were identified from May 2012 to April 2016. Eight patients had unfavorable tumor marker decline. Six were offered and received intensified chemotherapy (two T-BEPx3 + TIP and four T-BEPx2 + PEI + TIP). Serious toxicities included neutropenic sepsis, deep venous thrombosis, and C. difficile colitis, but there were no toxic deaths. One patient died of synchronous metastatic adenocarcinoma ex teratoma. The remaining five patients achieved marker-negative partial response, two had residual mature teratoma excised, and four have no evidence of disease after surgery. All are alive at a median of 63.5 months (range 46.3-65.6); one patient has grade 2 peripheral sensory neuropathy, and one patient has grade 2 cognitive disturbance. Of four patients treated with standard BEP, two have died of disease and two are alive at 51.4 and 53.6 months. CONCLUSIONS: Our experience with intensified chemotherapy for men with poor-prognosis GCC and unfavorable tumor marker decline confirms that it is feasible, reasonably safe, and appears to provide results similar to those reported in GETUG-13.
INTRODUCTION: Intensified chemotherapy improved outcomes for men with poor-prognosis metastatic germ cell cancer (GCC) and unfavorable tumor marker decline after one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy in the GETUG-13 trial. Herein, we report our experience to date using a similar approach. METHODS:Patients were identified from our electronic GCC database. Men with poor-prognosis GCC and unfavorable tumor marker decline were offered intensified chemotherapy consisting of T-BEP (three cycles) plus paclitaxel, ifosfamide, and cisplatin (TIP) (one cycle), along with prophylactic granulocyte-colony stimulating factor (G-CSF) and resection of residual masses. Cisplatin, etoposide, and ifosfamide (PEI) replaced the last cycle of T-BEP for bleomycin pulmonary concerns. Serious toxicities, progression-free survival, and overall survival were evaluated retrospectively. RESULTS: Ten patients with poor-prognosis GCC were identified from May 2012 to April 2016. Eight patients had unfavorable tumor marker decline. Six were offered and received intensified chemotherapy (two T-BEPx3 + TIP and four T-BEPx2 + PEI + TIP). Serious toxicities included neutropenic sepsis, deep venous thrombosis, and C. difficilecolitis, but there were no toxic deaths. One patient died of synchronous metastatic adenocarcinoma ex teratoma. The remaining five patients achieved marker-negative partial response, two had residual mature teratoma excised, and four have no evidence of disease after surgery. All are alive at a median of 63.5 months (range 46.3-65.6); one patient has grade 2 peripheral sensory neuropathy, and one patient has grade 2 cognitive disturbance. Of four patients treated with standard BEP, two have died of disease and two are alive at 51.4 and 53.6 months. CONCLUSIONS: Our experience with intensified chemotherapy for men with poor-prognosis GCC and unfavorable tumor marker decline confirms that it is feasible, reasonably safe, and appears to provide results similar to those reported in GETUG-13.
Authors: A Harstrick; H J Schmoll; C Bokemeyer; B Metzner; H J Illiger; W Berdel; H Ostermann; C Manegold; U Räth; W Siegert Journal: J Cancer Res Clin Oncol Date: 1991 Impact factor: 4.553
Authors: Karin Oechsle; Christian Kollmannsberger; Friedemann Honecker; Frank Mayer; Cornelius F Waller; Jörg T Hartmann; Ina Boehlke; Carsten Bokemeyer Journal: Eur Urol Date: 2011-06-24 Impact factor: 20.096
Authors: Torgrim Tandstad; Christian K Kollmannsberger; Bruce J Roth; Claudio Jeldres; Silke Gillessen; Karim Fizazi; Siamak Daneshmand; William T Lowrance; Nasser H Hanna; Costantine Albany; Richard Foster; Gabriella Cohn Cedermark; Darren R Feldman; Thomas Powles; Mark A Lewis; Peter Scott Grimison; Douglas Bank; Christopher Porter; Peter Albers; Maria De Santis; Sandy Srinivas; George J Bosl; Craig R Nichols Journal: J Clin Oncol Date: 2017-08-30 Impact factor: 44.544
Authors: Fabio Calabrò; Peter Albers; Carsten Bokemeyer; Chris Martin; Lawrence H Einhorn; Alan Horwich; Susanne Krege; Hans Joachim Schmoll; Cora N Sternberg; Gedske Daugaard Journal: Eur Urol Date: 2012-03-24 Impact factor: 20.096
Authors: R J Motzer; J Sheinfeld; M Mazumdar; M Bains; T Mariani; J Bacik; D Bajorin; G J Bosl Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: F Honecker; J Aparicio; D Berney; J Beyer; C Bokemeyer; R Cathomas; N Clarke; G Cohn-Cedermark; G Daugaard; K-P Dieckmann; K Fizazi; S Fosså; J R Germa-Lluch; P Giannatempo; J A Gietema; S Gillessen; H S Haugnes; A Heidenreich; K Hemminki; R Huddart; M A S Jewett; F Joly; J Lauritsen; A Lorch; A Necchi; N Nicolai; C Oing; J Oldenburg; D Ondruš; A Papachristofilou; T Powles; A Sohaib; O Ståhl; T Tandstad; G Toner; A Horwich Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl Journal: J Clin Oncol Date: 2007-01-20 Impact factor: 44.544
Authors: J Shamash; S-J Sarker; R Huddart; S Harland; J K Joffe; D Mazhar; A Birtle; J White; K Chowdhury; P Wilson; M R Marshall; S Vinnicombe Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976